专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0175165A3 SCREENING MARKERS AND METHODS FOR NEURODEGENERATIVE DISORDERS 审中-公开
标题翻译：筛选标记和神经损伤病症的方法
公开(公告)号：WO0175165A3
公开(公告)日：2002-10-31
申请号：PCT/US0110247
申请日：2001-03-30
申请人： ELAN PHARM INC , MCCONLOGUE LISA C , GAMES KATE D , YEDNOCK THEODORE A , HUA TAN , MESSERSMITH ELIZABETH , BARD FREDERIQUE
发明人： MCCONLOGUE LISA C , GAMES KATE D , YEDNOCK THEODORE A , HUA TAN , MESSERSMITH ELIZABETH , BARD FREDERIQUE
IPC分类号： C12Q1/68 , A01K67/027
CPC分类号： C12Q1/6883 , A01K2217/05 , A01K2227/105 , A01K2267/0312 , C12Q2600/158
摘要： The invention includes identification of specific markers, the elevation of which in central nervous tissue is associated with Alzheimer's Disease. The invention also includes improved assay methods for selecting compounds useful in reducing or preventing onset of the pathology with Alzheimer's Disease.
摘要翻译：本发明包括特定标志物的鉴定，其中心神经组织的高度与阿尔茨海默病有关。本发明还包括用于选择可用于减少或预防阿尔茨海默病病理发病的化合物的改进的测定方法。

2. 发明申请

WO2005000246A3 METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS 审中-公开
公开(公告)号：WO2005000246A3
公开(公告)日：2005-11-24
申请号：PCT/US2004020280
申请日：2004-06-25
申请人： ELAN PHARM INC , YEDNOCK THEODORE A , FREEDMAN STEPHEN B , LIEBERBURG IVAN , PLEISS MICHAEL A , KONRADI ANDREI W , SHOPP GEORGE , MESSERSMITH ELIZABETH
发明人： YEDNOCK THEODORE A , FREEDMAN STEPHEN B , LIEBERBURG IVAN , PLEISS MICHAEL A , KONRADI ANDREI W , SHOPP GEORGE , MESSERSMITH ELIZABETH
IPC分类号： A61K20060101 , A61K31/16 , A61K31/18 , A61K31/195 , A61K31/40 , A61K31/415 , A61K31/425 , A61K31/44 , A61K31/519 , A61K31/525 , A61K38/00 , A61K39/00 , A61K39/395
CPC分类号： A61K31/519 , A61K39/39541 , A61K2300/00
摘要： This application relates to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to alpha 4 integrin or an immunologically active antigen binding fragment in therapeutically effective amounts. The application also relates generally to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and small molecule alpha-4 integrin antagonist that inhibits the alpha-4 integrin ( 4 integrin) interaction with VCAM-1. The invention further relates to methods of preparing the compounds and methods of using the compounds and compositions.

3. 发明申请

WO2005000244A3 METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS 审中-公开
标题翻译：治疗类风湿关节炎的方法和组合物
公开(公告)号：WO2005000244A3
公开(公告)日：2005-09-29
申请号：PCT/US2004020240
申请日：2004-06-25
申请人： ELAN PHARM INC , YEDNOCK THEODORE A , FREEDMAN STEPHEN B , LIEBERBURG IVAN , PLEISS MICHAEL A , KONRADI ANDREI W , SHOPP GEORGE , MESSERSMITH ELIZABETH
发明人： YEDNOCK THEODORE A , FREEDMAN STEPHEN B , LIEBERBURG IVAN , PLEISS MICHAEL A , KONRADI ANDREI W , SHOPP GEORGE , MESSERSMITH ELIZABETH
IPC分类号： A61K20060101 , A61K31/16 , A61K31/18 , A61K31/195 , A61K31/40 , A61K31/415 , A61K31/425 , A61K31/44 , A61K31/519 , A61K31/525 , A61K38/00 , A61K39/00 , A61K39/395
CPC分类号： A61K31/519 , A61K39/39541 , A61K2300/00
摘要： This application relates to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to alpha 4 integrin or an immunologically active antigen binding fragment in therapeutically effective amounts. The application also relates generally to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and small molecule alpha-4 integrin antagonist that inhibits the alpha-4 integrin ( 4 integrin) interaction with VCAM-1. The invention further relates to methods of preparing the compounds and methods of using the compounds and compositions.
摘要翻译：本申请涉及用于治疗类风湿性关节炎的方法和组合物，其通过施用包含甲氨蝶呤和抗α4整联蛋白或免疫活性抗原结合片段的治疗有效量的组合疗法。本申请一般还涉及通过施用包含甲氨蝶呤和抑制α-4整联蛋白（4整联蛋白）与VCAM-1相互作用的小分子α-4整联蛋白拮抗剂的组合疗法来治疗类风湿性关节炎的方法和组合物。本发明还涉及制备该化合物的方法和使用该化合物和组合物的方法。

4. 发明申请

WO2007103112A3 METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB 审中-公开
标题翻译：用NATALIZUMAB治疗炎症和自身免疫疾病的方法
公开(公告)号：WO2007103112A3
公开(公告)日：2007-11-29
申请号：PCT/US2007005265
申请日：2007-03-02
申请人： ELAN PHARM INC , YEDNOCK THEODORE A
发明人： YEDNOCK THEODORE A
IPC分类号： A61K39/395
CPC分类号： G01N33/6854 , A61K39/39541 , A61K2039/505 , A61K2039/545 , C07K16/2839 , C07K16/2842 , A61K2300/00
摘要： Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 levels across patients or within a single patient across time may change the pharmacokinetic profile of natalizumab. Patients with lower levels of IgG4 may experience higher nadir levels of natalizumab during a dosing period. Monitoring IgG4 and/or bivalent natalizumab levels, and determining a dose or dosage period based on the monitoring may improve the safety and/or efficacy of natalizumab therapy.
摘要翻译：纳他珠单抗对于炎性和自身免疫疾病如多发性硬化，克罗恩病和类风湿性关节炎是一种安全有效的治疗方法。那他珠单抗和IgG4分子之间的链交换用于降低给予natalizumab后存在的二价natalizumab的水平，从而降低该natalizumab在患者体内的活性。跨越患者或跨越单个患者的IgG4水平的差异可能改变那他珠单抗的药代动力学特征。在给药期间，具有较低水平的IgG4的患者可能经历更高的天竺葵素水平。监测IgG4和/或二价那他珠单抗水平，并且基于监测确定剂量或剂量周期可以提高那他珠单抗治疗的安全性和/或疗效。

5. 发明申请

WO2014039975A2 ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE 审中-公开
标题翻译：抗MCAM抗体和相关的使用方法
公开(公告)号：WO2014039975A2
公开(公告)日：2014-03-13
申请号：PCT/US2013058773
申请日：2013-09-09
申请人： NEOTOPE BIOSCIENCES LTD , FLANAGAN KENNETH , BAKER JEANNE , YEDNOCK THEODORE A
发明人： FLANAGAN KENNETH , BAKER JEANNE , YEDNOCK THEODORE A
IPC分类号： A61K39/395
CPC分类号： C07K16/3092 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/30 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin alpha-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
摘要翻译：本文描述了能够抑制MCAM及其配体之间的相互作用的抗MCAM抗体及其抗原结合片段，包括层粘连蛋白α-4链的蛋白质。这些抗MCAM抗体及其抗原结合片段可用于例如治疗以表达MCAM的细胞浸润到体内炎症部位为特征的炎性病症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式